Abstract:
Multiple myeloma (MM) is a malignant disease characterized by an uncontrolled proliferation of plasma cells in the bone marrow, and accounts for 10% of hematological cancers. It is a high-burden hemopathy, and represents a challenge for healthcare structures. It is characterized by a pattern of persistent recurrence, with each progression becoming more aggressive and more insensitive to treatment, and the duration of each remission becoming shorter than the previous one. On the basis of these data, we carried out an analysis of direct medical costs in order to gain precise knowledge of the expenditure devoted to the care of patients suffering from this haemopathy.
|